pharmaceuticals
pharmaceuticals
Lonza Partners with CMAC for Advanced Drug Manufacturing
🌟 Lonza joins CMAC in Glasgow! This partnership boosts particle technology and enhances drug manufacturing efficiency. 🤝💊 PharmaInnovation ContinuousManufacturing
Revolutionary Tech Transforms Pharmaceutical Freeze-Drying!
🔍 Discover LyoVIS®! A game-changing technology for monitoring freeze-drying in pharmaceuticals, enhancing drug stability and addressing scale-up challenges. 💡✨
Samabriva Unveils High-Tech Plant-Based Factory in Belgium!
🌱 Exciting news! Samabriva opens a new biomanufacturing facility in Belgium, focusing on high-value natural molecules for pharmaceuticals. 💰🚀
Ligand Pharma Snaps Up Apeiron Biologics for $100M
📢 Ligand Pharma acquires Apeiron Biologics for $100M, invests $4M in invIOs Holding AG, and offers future event-based considerations. 🏢💰🏥🤝📅
Revolutionary Supor Prime Filters: The Ultimate Solution for High-Concentration Therapies
🔍 Discover Supor Prime Filters: a reliable filtration solution for high-concentration therapies, ensuring safe and effective manufacturing processes. 🌡️💧🔬💪🏥
Discover the Versatile Marvel of Albumin
💪 Albumin plays a crucial role in the body, from maintaining osmotic pressure to transporting molecules and preventing oxidative damage. 🔬 💊 Its diverse uses in pharmaceuticals, vaccine production, and biomedical coatings make it a valuable resource. 💡 🌍 The global albumin market is expanding, with recombinant albumins leading the way in medical applications. 📈
Sandoz Acquires Lucentis for $170 Million Boosting Ophthalmology Portfolio and Expanding Global Access
📰 Sandoz acquires Coherus' Lucentis for $170m, expanding its ophthalmology portfolio. 💰 Lucentis treats eye diseases worldwide.
Pharma’s Tech Revolution: AI and Synbio Supercharge Biologics
📰 Pharma is using new technologies like AI and synthetic biology to maximize biologics manufacturing. 💊 Innovations are improving antibody stability and yield, accelerating production and drug development. 🌐
Goldman Sachs Raises $650 Million for Life Sciences Investments: A Game-Changer for Medical Innovations
🏦 Goldman Sachs raises $650m for life sciences investments, showing growing interest in the sector. 💼🔬💰
Alfasigma SpA’s €170m Deal Expands Filgotinib Business
📅 On January 2nd, 2024, Alfasigma SpA 💪 signed a €170m deal with Galapagos NV to expand their pipeline and market presence 🌍. Additionally, former Galapagos CCO, Michele Manto, joins Alfasigma as CCO Western Europe. 💼
